Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Year Of Mandatory Reports Shows Safety-Monitoring Value Of AER Data

This article was originally published in The Tan Sheet

Executive Summary

The spike in dietary supplement adverse event reports in 2008 demonstrates that mandatory reporting gives FDA a more effective safety surveillance tool than voluntary reporting alone

You may also be interested in...



Hydroxycut Recall Sheds Light On Pros And Cons Of AER System

Identifying possible risks linked to dietary supplements - such as the recalled line of Hydroxycut weight-loss products - is challenging because FDA generally works with post-market information, an agency executive said

FDA Audits Of Supplement, OTC AERs Likely Starting This Year – Consultant

Dietary supplement and OTC drug companies should not become accustomed to the "honeymoon" FDA has allowed from adverse event reporting compliance audits, according to Rick Kingston, an executive with SafetyCall adverse event reporting call center

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS102918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel